Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib

Introduction Our patient treated with pembrolizumab and axitinib is one of the longest survivors in Japan on KEYNOTE 426, despite adverse events, including delayed‐onset hepatitis. We herein present a detailed clinical course and short discussion on the case. Case presentation This was a 49‐year‐old...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Koshiro Nishimoto, Suguru Shirotake, Yu Miyama, Go Kaneko, Kent Kanao, Daisuke Igarashi, Takayuki Takahashi, Yuta Umezawa, Masanori Yasuda, Masafumi Oyama
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wiley 2022-05-01
Reeks:IJU Case Reports
Onderwerpen:
axitinib
KEYNOTE426
metastatic renal cell carcinoma
pembrolizumab
Online toegang:https://doi.org/10.1002/iju5.12422
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items